High-Purity Baricitinib API Powder for Immunomodulatory Applications
Feb 05, 2026
Leave a message
Introduction
In the evolving landscape of precision medicine, Baricitinib (CAS: 1187594-09-7) has emerged as a cornerstone molecule for treating complex autoimmune phenotypes. As a strategic B2B supplier, Xi'an Tihealth Biotechnology Co., Ltd. recognizes that the success of a therapeutic intervention depends entirely on the structural integrity and chemical consistency of the API. This analysis moves beyond basic pharmacology to explore the critical synthesis logic and clinical milestones that define Baricitinib's industry value.
Technical Insight: Managing Process Impurities & Crystalline Stability
The primary challenge in industrializing Baricitinib API lies not in achieving purity, but in the micro-management of the synthesis environment. At Xi'an Tihealth, we prioritize the strain control of the Azetidine ring and the conversion efficiency of key intermediates.
Our R&D team has identified that during the de-protection phase, the formation of trace lactone impurities is a significant risk due to their close polarity to the main compound. By implementing Quality by Design (QbD) principles-precisely maintaining the reaction pH within a narrow neutral range (7.0-7.5) and utilizing continuous flow micro-reaction technology-we consistently reduce individual impurities to below 0.05%. Furthermore, to guarantee shelf-life stability, we utilize real-time XRPD monitoring to ensure that our anhydrous Form I crystals remain stable even under accelerated conditions (40°C/75%RH) for 24 months.
Clinical Evolution: Targeted Intervention Beyond Conventional Boundaries
The pharmacological value of Baricitinib is currently shifting from "broad anti-inflammation" to "precision immune remodeling." At the research level, its role as a selective JAK1/JAK2 modulator offers a unique window into treating unmet medical needs.
Recent clinical datasets, including the long-term BRAVE-AA studies, highlight that Baricitinib's efficacy in severe Alopecia Areata is driven by its sustained regulation of the IFN-γ signaling pathway within the hair follicle microenvironment. With a half-life of approximately 12.5 hours, it provides clinicians with an ideal window for dosage titration. Moreover, emerging explorations in Systemic Lupus Erythematosus (SLE) suggest that the molecule's ability to mitigate joint and skin involvement paves the way for future specialized delivery systems, such as sustained-release or topical formulations.
Why Xi'an Tihealth is the Partner of Choice for Baricitinib API
As a global leader in raw material distribution since 2008, serving over 1,500 clients, Xi'an Tihealth offers more than just a product; we offer a compliance-driven partnership:
Analytical Depth: Every batch is verified via H-NMR, LC-MS, and HPLC, ensuring that the "impurity burden" is minimized for clinical reliability.
Regulatory Alignment: Our production strictly adheres to ISO 9001:2015 and ICH Q3A guidelines, simplifying the registration and audit process for pharmaceutical manufacturers.
Scalable Logistics: From mg-scale research samples to MT-scale commercial batches, we ensure a stable, audit-ready supply chain.
Future Outlook: The Intersection of AI and Green Synthesis
The future of Baricitinib production lies in sustainability and efficiency. Xi'an Tihealth is actively investing in enzymatic catalysis and AI-driven route optimization to reduce environmental footprints while maintaining the highest purity standards. As immunotherapy continues to diversify, Baricitinib remains a vital asset in the global pharmacopeia.
References
Eli Lilly & Incyte (Originator Data): Clinical pharmacology and safety profiles of Olumiant.
https://www.olumiant.com/
PubChem Database (NIH): Structural and biological activity data for Baricitinib (CID: 44205240).
https://pubchem.ncbi.nlm.nih.gov/compound/Baricitinib
FDA Center for Drug Evaluation: Approval reports and regulatory briefings for JAK inhibitors.
https://www.accessdata.fda.gov/
ClinicalTrials.gov: Current status of Baricitinib trials in SLE and Alopecia Areata.
https://clinicaltrials.gov/
ICH Quality Guidelines: Standards for impurities in new drug substances (Q3A).
https://www.ich.org/page/quality-guidelines
Send Inquiry





